5 research outputs found

    DN4, a novel cell surface molecule on cortical epithelial cells of the human thymus : The Biochemical analysis and expression pattern of DN4 in normal tissues

    No full text
    학위논문(박사)--서울대학교 대학원 :의학과 병리학전공,1996.Docto

    유전 프로그래밍을 이용한 Technical Trading rule 의 발견에 관한 연구

    No full text
    학위논문(석사)--서울대학교 대학원 :경영학과 경영학 전공,2001.Maste

    The Development of the Scale of Morality(SM) for Elementary School Students

    No full text

    Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis

    No full text
    Tumor hypoxia and aerobic glycolysis are well-known resistance factors for anticancer therapies. Here, we demonstrate that tumor-associated macrophages (TAM) enhance tumor hypoxia and aerobic glycolysis in mice subcutaneous tumors and in patients with non-small cell lung cancer (NSCLC). We found a strong correlation between CD68 TAM immunostaining and PET 18fluoro-deoxyglucose (FDG) uptake in 98 matched tumors of patients with NSCLC. We also observed a significant correlation between CD68 and glycolytic gene signatures in 513 patients with NSCLC from The Cancer Genome Atlas database. TAM secreted TNF alpha to promote tumor cell glycolysis, whereas increased AMP-activated protein kinase and peroxisome proliferator-activated receptor gamma coactivator 1-alpha in TAM facilitated tumor hypoxia. Depletion of TAM by clodronate was sufficient to abrogate aerobic glycolysis and tumor hypoxia, thereby improving tumor response to anticancer therapies. TAM depletion led to a significant increase in programmed death-ligand 1 (PD-L1) expression in aerobic cancer cells as well as T-cell infiltration in tumors, resulting in antitumor efficacy by PD-L1 antibodies, which were otherwise completely ineffective. These data suggest that TAM can significantly alter tumor metabolism, further complicating tumor response to anticancer therapies, including immunotherapy. Significance: These findings show that tumor-associated macrophages can significantly modulate tumor metabolism, hindering the efficacy of anticancer therapies, including anti PD-L1 immunotherapy.11sciescopu
    corecore